Cargando…

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

PURPOSE: Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. METHODS: Patients received cemiplimab 250 mg (n = 6) or 350 mg (n = 7) e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitano, Shigehisa, Shimizu, Toshio, Koyama, Takafumi, Ebata, Takahiro, Iwasa, Satoru, Kondo, Shunsuke, Shimomura, Akihiko, Fujiwara, Yutaka, Yamamoto, Noboru, Paccaly, Anne, Li, Siyu, Rietschel, Petra, Sims, Tasha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801352/ https://www.ncbi.nlm.nih.gov/pubmed/33146741 http://dx.doi.org/10.1007/s00280-020-04161-6

Ejemplares similares

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
por: Koyama, Takafumi, et al.
Publicado: (2020)

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
por: Shimomura, Akihiko, et al.
Publicado: (2017)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
por: Fujiwara, Yutaka, et al.
Publicado: (2020)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
por: Yang, Feng, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
por: Kondo, Shunsuke, et al.
Publicado: (2022)

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
por: Nguyen, Jenny‐Hoa, et al.
Publicado: (2022)

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis
por: Paccaly, Anne J., et al.
Publicado: (2021)

PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy
por: Lu, Dan, et al.
Publicado: (2022)

Practical consideration for successful sequential tumor biopsies in first-in-human trials
por: Koyama, Takafumi, et al.
Publicado: (2022)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

Cemiplimab-Induced Alopecia Areata
por: Piraccini, Bianca Maria, et al.
Publicado: (2023)

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
por: Gogishvili, Miranda, et al.
Publicado: (2022)

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Cemiplimab-Associated Sinusoidal Obstruction Syndrome
por: Sarsour, Nadeen Y., et al.
Publicado: (2023)

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study
por: Gümüş, Mahmut, et al.
Publicado: (2022)

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
por: Denis, Chloé, et al.
Publicado: (2021)

Intravascular squamous cell carcinoma treated with cemiplimab
por: Rose, Alexander N., et al.
Publicado: (2021)

Self‐resolving bullous pemphigoid induced by cemiplimab
por: Molle, Mattia Fabio, et al.
Publicado: (2022)

Clinical Development of Immune Checkpoint Inhibitors
por: Ito, Ayumu, et al.
Publicado: (2015)

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
por: Kuboki, Yasutoshi, et al.
Publicado: (2022)

Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
por: Davis, Christina M., et al.
Publicado: (2022)

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
por: Goodman, D.T.
Publicado: (2022)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022)

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?
por: Boziou, Maria, et al.
Publicado: (2023)

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
por: Feliciano, Josephine Louella, et al.
Publicado: (2023)

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
por: Mizuno, Takaaki, et al.
Publicado: (2022)

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
por: Carlo‐Stella, Carmelo, et al.
Publicado: (2022)

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
por: Lesokhin, Alexander, et al.
Publicado: (2023)

Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab
por: Huang, Ye, et al.
Publicado: (2023)

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
por: Van Meerhaeghe, T., et al.
Publicado: (2022)

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
por: Doi, Toshihiko, et al.
Publicado: (2021)

Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis
por: Grace de Lima, Stacy, et al.
Publicado: (2023)

Combined cemiplimab and radiotherapy for advanced basal cell carcinoma: A case report
por: Sarfaraz, Sidra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3egjo26oimuecr8n8oub9ckpo2